Publication:

Plant-based antibodies and virus-like particles: a leap towards new therapeutic development

The generation of therapeutic antibodies and fusion proteins for medical application is one of the fastest growing areas of the pharmaceutical industry with more than 150 therapeutic antibodies and fusion proteins currently either in clinical trial or use. At the same time, the use of virus-like particles has become an interesting tool in the fight against viral infections. Thus, some devastating high-incidence diseases such as HIV or cancer are currently chosen as clear targets for this type of therapeutical strategy. However, the high production cost of the current manufacturing systems of these molecules is a latent hurdle to overcome. With the advent of biotechnology, transgenic plants have emerged as a more economical new strategy for recombinant protein production. Antibodies and virus-like particles have been demonstrated to be well expressed in plants. In addition, the achieved protein expression level of most of them in the plant system has been reported to be compatible with that established for commercial viability. These facts make the use of plants for the generation of these types of recombinant molecules a very promising strategy to the development of lower cost biopharmaceuticals. In consequence, it could lead to exert important economical and medical implications as being affordable for developing countries where the incidence of infectious diseases is the highest. The development and production of these therapeutic molecules in plants is reviewed in this chapter, and the medical implications, advantages and limitations of both the plant-system and plant-derived molecules for practical use are discussed.